Revealing the heterogeneity of treatment resistance in less‐defined subtype diffuse large B cell lymphoma patients by integrating programmed cell death patterns and liquid biopsy
Abstract Precision medicine in less‐defined subtype diffuse large B‐cell lymphoma (DLBCL) remains a challenge due to the heterogeneous nature of the disease. Programmed cell death (PCD) pathways are crucial in the advancement of lymphoma and serve as significant prognostic markers for individuals af...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2025-01-01
|
| Col·lecció: | Clinical and Translational Medicine |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/ctm2.70150 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
